Nosch Labs, CSIR-IICT ink pact for transfer of process knowhow to make anti-Covid drug 2-DG
Hyderabad: CSIR-Indian Institute of Chemical Technology (IICT) and Nosch Labs have entered into a non-exclusive agreement for transfer of the process knowhow for synthesis of anti-Covid-19 drug 2-DG (2-Deoxy -D - Glucose).
A press release here on Monday said as per the pact signed on June 11, Nosch Labs would commence manufacture of 2-DG drug after obtaining regulatory clearances from the Drugs Controller General of India (DCGI).
The company intends to make the drug available at an affordable price, the release said.
Srivari Chandrasekhar, Director of CSIR-IICT, said the institute has been instrumental in addressing numerous societal challenges and providing innovative solutions to Indian industries in the area of drugs and pharmaceuticals, agrochemicals, lipids, catalysis, functional materials, environmental, analytical, biological and engineering sciences.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.